This trial is evaluating whether Positron Emission Tomography will improve 2 primary outcomes and 13 secondary outcomes in patients with Metastatic NUT Carcinoma. Measurement will happen over the course of Up to 21 days of each cycle.
This trial requires 55 total participants across 1 different treatment group
This trial involves a single treatment. Positron Emission Tomography is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
"Carcinoma is frequently asymptomatic. It rarely appears as a painless mass. It is more frequently a mass present on imaging studies. Pain is a common feature of carcinoma, but is also noted in a wide variety of diseases. Symptoms are not specific to any tumor. Patients with a history of skin cancer are at increased risk for developing squamous cell carcinoma of the oral cavity or other sites or are at greater risk for presenting with squamous cell carcinoma of the head and neck. Lymph node involvement increases the likelihood of oral squamous cell carcinoma. Squamous cell carcinoma of the head and neck is an absolute indication for mandibular or maxillary reconstruction." - Anonymous Online Contributor
"This survey confirms the use of chemotherapy, surgical resection, and the use of radiation therapy for cancer patients within the last 12 months. However, the use of hormonal therapy for breast cancer patients during this time period has decreased, which leads us to propose that hormone-sensitive cancers are now being addressed with hormonal therapy." - Anonymous Online Contributor
"Carcinoma is a disorder of uncontrolled cell growth of epithelial cell tumors. Carcinoma is the leading cause of cancer death in children and teenagers. Carcinoma accounts for about 80% of malignant neoplasm in the USA." - Anonymous Online Contributor
"Cancer incidence in the US has increased since the mid-1990s. In addition, there are differences in cancer incidence between blacks and whites. The average age at diagnosis is late, as more people are surviving longer." - Anonymous Online Contributor
"The evidence regarding the carcinogenic effects of dietary factors is fairly poor. However, dietary factors are commonly related to many cancers, and many cancers occur in an orderly sequence that suggests pathogenetic processes. It is conceivable that dietary factors play a part in the development of many cancers, perhaps acting via interaction with the environment as well as by direct influence on cells. Furthermore, the observation that many cancers are linked to smoking and alcohol drinking further suggests that exposures to carcinogenic substances are involved." - Anonymous Online Contributor
"Adenocarcinoma of the prostate is a rarity and metastasis is an exceedingly rare finding in prostate adenocarcinoma. Radical prostatectomy as well as external beam radiotherapy remains the best treatment options. To the authors' knowledge, only a few studies have addressed the topic of surgical salvage of localized recurrent disease or in combination with pelvic lymphadenectomy. Results from a recent clinical trial from this retrospective, single institution database case series reveal that patients with biochemical parameters of relapse can potentially be cured. These patients have demonstrated complete remissions with surgical salvage. Results from a recent clinical trial warrant further investigation to determine which patients will benefit from salvage surgery with concurrent or sequential pelvic lymphadenectomy." - Anonymous Online Contributor
"As there have been advances in chemotherapy and radiation therapy in last decades, there have been few new discoveries for improving quality of life and survival for metastatic carcinoma patients. As we have no evidence from recent studies of improved survival and quality of life, we can only conclude that there is no new method to treat metastatic carcinoma patients." - Anonymous Online Contributor
"This meta-analysis suggests that cisplatin is significantly more effective than a placebo with respect to tumour response rate and CRP clearance in patients diagnosed with advanced non-small-cell lung carcinoma or head and neck cancer who receive no prior chemotherapy." - Anonymous Online Contributor
"The survival rate of patients with carcinoma is very low in the Korean population. The prognosis of cancer is significantly more poor than that of inpatient patients." - Anonymous Online Contributor
"DDP continues to be a powerful treatment, with the potential to improve patient outcomes and help lower the burden of ovarian cancer. A careful balance of tumour response rate with patient risk factors must be considered. Further investigation is warranted into molecular effects and the potential to improve clinical trials evaluating DDP." - Anonymous Online Contributor
"The use of the current high dose (80 mg/m2) of cisplatin is safe. The use of cisplatin infusion might not be necessary in children>16 years." - Anonymous Online Contributor
"Cisplatin is an effective anti-cancer drug, but it may present an increased risk of serious adverse events that sometimes require hospitalization or medical treatment. The most common adverse reactions were hemorrhagic cystitis and nephrotoxicity." - Anonymous Online Contributor